Persistence and Adherence to Ofatumumab Treatment in Adults with Relapsing Multiple Sclerosis
This observational study is planned to assess how many patients with relapsing multiple sclerosis continue and adhere to ofatumumab treatment over time, with a target of about 5000 participants. Follow-up will occur at 6 months, 12 months, and up to 4 years, but no results are currently available as they have not been reported.
- Tags
- #Other
- Most relevant to
- —
- Source
- Read original source
- Human efficacy
- Not applicable – no treatment tested
- Mechanism
- Not reported
- Evidence strength
- No results yet
- Outcome
- Ongoing – no results yet
Why it matters
Understanding patient adherence and persistence can provide insights into treatment effectiveness in real-world settings, potentially guiding future MS treatment strategies.
What this does not prove
No results are posted, and the study's planned enrollment and endpoints do not constitute findings.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Observational
- Participants / samples
- 5000 · estimated
- Randomised
- No
- Controlled
- No
- Primary endpoint met
- Not reported
- Relevant MS type
- RRMS, SPMS
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- Not reported
- Research areas
- Other
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- Not reported
- Size of effect
- Not reported
- Secondary endpoints
- Number of Treatments Used; Number of Patients by Sequence of Treatments Used; Number of Patients by Line of Therapy (LOT); Number of Patients by Type of Treatment; Duration of Treatment; Percentage of Patients Who Switch Treatment; Percentage of Patients Who Discontinue OMB Treatment; Number of Patients by Treatments Received After OMB Treatment; Baseline Demographics; Number of Patients by Index Year (year of first claim for OMB or DMT)
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
Supporting passages (18)
study phaseStudy type: Observational
study designStudy type: Observational
subjectsParticipants: people; ages from 18 Years to 100 Years; sex All
sample sizeEnrollment: 5000 participants (estimated)
sample size basisEnrollment: 5000 participants (estimated)
randomizedNo results are posted.
controlledNo results are posted.
peer reviewedTrial registry record.
research categories"briefSummary": "This study aims to evaluate the real-world persistence and adherence to ofatumumab (OMB) treatment in adult patients with relapsing multiple sclerosis (RMS).
relevant ms typesConditions: Multiple Sclerosis
intervention"briefSummary": "This study aims to evaluate the real-world persistence and adherence to ofatumumab (OMB) treatment in adult patients with relapsing multiple sclerosis (RMS).
primary endpointPrimary endpoints: Proportion of Patients Persistent With OMB; Proportion of Patients Adherent to OMB
follow upFollow-up: 6 months, 12 months; Baseline, up to approximately 4 years
limitationsNo results are posted.
secondary endpoints"measure": "Number of Patients by Sequence of Treatments Used",
outcomeNo results are posted.
human efficacyTrial registry record.
findingsTrial registry record. Publication date: unknown. No results are posted. Planned enrolment and endpoints are not findings.
AI assessment, not yet reviewed by a person · version 3 · Community votes are separate from evidence review.